All In Biotech

Drug Trial Radar · NCT02263547

Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride

Last checked: Nov 20, 2026Latest source record: Apr 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

14

Actual

Start

Mar 2015

Primary completion

Jun 2016

Study completion Jun 2016

Sponsor

Lead sponsor
Derrick Scott RobertsonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Genzyme, a Sanofi Company; University of South Florida
First posted
Oct 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective To determine if colestipol hydrochloride tablets can accelerate the elimination of teriflunomide. Teriflunomide will be administered for 14 days followed by colestipol dosing of 11 days. Total duration of the study is 40 days. Secondary Objectives To collect information on the pattern of side effects with use of colestipol hydrochloride after teriflunomide administration and to determine the best duration of therapy needed for adequate elimination

Conditions

  • Teriflunomide Elimination
  • Healthy Volunteers

Interventions

  • teriflunomideDrug

  • ColestipolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome Measures: Teriflunomide Concentrations at Day 28Time frame: 28 days after the start in the study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • USF Carol and Frank Morsani Center for Advanced Healthcare

    Tampa, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.